NCT00120861已完成2 期
A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of NM283 and the Combination of Pegylated Interferon Plus NM283, in Patients With Chronic Hepatitis C Who Have Previously Failed to Respond to Standard Therapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 11
研究概览
简要总结
This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment with pegylated interferon plus ribavirin, the current standard therapy for treatment of hepatitis C viral infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented clinical history compatible with chronic hepatitis C and compensated liver disease
- •Failed response to previous hepatitis C therapy of pegylated interferon/ribavirin
- •Other protocol-defined inclusion criteria may apply.
排除标准
- •Patient is pregnant or breastfeeding
- •Patient is co-infected with hepatitis B or HIV
- •Other protocol-defined exclusion criteria may apply.
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate Drug-drug Interaction Between Valopicitabine and RibavirinChronic Hepatitis CNCT00395421Merck Sharp & Dohme LLC114
进行中（未招募）
1 期
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung CancerNon-small Cell Lung CancerNCT06114511Sichuan Baili Pharmaceutical Co., Ltd.78
终止
2 期
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney DiseaseGoutChronic Kidney DiseasesHyperuricemiaNCT04987294Allena Pharmaceuticals19
招募中
1 期
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationNon Small Cell Lung CancerNCT05641493Shanghai Henlius Biotech49
已完成
1 期
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsImmune Thrombocytopenia (ITP)NCT03951623Hutchison Medipharma Limited45